source
- Novartis signs $7.8 billion deal with Abogen for mRNA-encoded autoimmune T-cell engagerNovartis announced it will pay $575 million upfront to Abogen Biosciences for an mRNA-encoded T-cell engager that has shown early clinical activity in autoimmune disease. The agreement includes up…
- Novartis pays $575 million upfront for access to Chinese biotech Abogen’s RNA platform and option on ABO-2203Novartis announced a deal with China‑based Abogen Biosciences that could be worth up to $7.8 billion. The agreement includes an upfront payment of $575 million. Under the deal, Abogen will provide…